Floatz logo

ALLOGENEIC HUMAN UMBILICAL CORD BLOOD

Large-cell Lymphoma

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Large-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2B
Equine Atg
Masonic Cancer Center, University of Minnesota
Phase 2B
Umbilical Cord Blood Mononuclear Cells
Masonic Cancer Center, University of Minnesota
Phase 2B
SPANLECORTEMLOCEL
Novartis Pharmaceuticals
Phase 1/2CCC
Treg Cells
Masonic Cancer Center, University of Minnesota
Phase 2CCC

View all 9 →

Same molecule, other indications

ALLOGENEIC HUMAN UMBILICAL CORD BLOOD is also rated in:

acute lymphoblastic leukemiaDormant
B
Indicative ·
61 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
59 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →